Nomura Asset Management Co. Ltd. boosted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 2.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,584 shares of the medical research company’s stock after purchasing an additional 112 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Bio-Rad Laboratories were worth $3,464,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the business. Qube Research & Technologies Ltd boosted its stake in Bio-Rad Laboratories by 26.2% in the 4th quarter. Qube Research & Technologies Ltd now owns 29,804 shares of the medical research company’s stock worth $22,519,000 after purchasing an additional 6,194 shares during the period. Raymond James Trust N.A. boosted its position in shares of Bio-Rad Laboratories by 11.0% during the 4th quarter. Raymond James Trust N.A. now owns 475 shares of the medical research company’s stock valued at $359,000 after acquiring an additional 47 shares during the last quarter. Xponance Inc. boosted its position in shares of Bio-Rad Laboratories by 2.1% during the 4th quarter. Xponance Inc. now owns 12,848 shares of the medical research company’s stock valued at $9,708,000 after acquiring an additional 260 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its position in shares of Bio-Rad Laboratories by 6.0% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 54,772 shares of the medical research company’s stock valued at $41,382,000 after acquiring an additional 3,088 shares during the last quarter. Finally, CWM LLC bought a new position in shares of Bio-Rad Laboratories during the 4th quarter valued at approximately $147,000. Institutional investors and hedge funds own 64.58% of the company’s stock.
A number of research analysts have recently commented on BIO shares. StockNews.com started coverage on Bio-Rad Laboratories in a research report on Thursday, March 31st. They set a “hold” rating for the company. Citigroup increased their target price on Bio-Rad Laboratories from $750.00 to $800.00 in a research report on Friday, February 11th.
Bio-Rad Laboratories (NYSE:BIO – Get Rating) last issued its quarterly earnings results on Thursday, February 10th. The medical research company reported $3.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.87 by $0.34. The company had revenue of $732.80 million during the quarter, compared to the consensus estimate of $731.94 million. Bio-Rad Laboratories had a return on equity of 3.70% and a net margin of 145.28%. Bio-Rad Laboratories’s revenue was down 7.2% on a year-over-year basis. During the same period last year, the company earned $4.01 earnings per share. On average, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 13.8 EPS for the current year.
Bio-Rad Laboratories Profile (Get Rating)
Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.
- Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO)
- It’s Personal: 3 Personal Care Stocks to Own in Volatile Markets
- Conagra Stock Has More Room to Grow
- 3 Recession-Proof Stocks to Buy Now
- MarketBeat: Week in Review 4/4 – 4/8
- 3 Best Life Sciences Stocks to Buy Now
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.